Pharmaceutical Grade Antidepressant Agents CAS 56296-78-7 Fluoxetine Hydrochloride/ Fluoxetine

• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >98%
• Model NO.: TGY201904150701
• Product Name: Pharmaceutical Grade Antidepressant Drug Fluoxetin
• Appearance: White Powder
• Molecular Formula: C17h19clf3no
• MW: 345.79
• Certificate: ISO 9001, USP
• Shelf Life: 24 Months
• Storage: Cool Dry Area
• Grade: Pharmaceutical Grade
• CAS No.: 56296-78-7
• Sample: Available
• Service: OEM
• MOQ: Any Quantity
• Assay: 98%Min, 99% HPLC
• Test Method: USP
• Application: Pharmaceutical Raw Intermediates
• Transport Package: Boil Bag
• Specification: HPLC 99%
• Trademark: TGY
• Origin: Xi′an, Shaanxi, China (Mainland)
• HS Code: 3001200020
• Production Capacity: 3000kg/Month

Product Description

1.Quick Details of Fluoxetine 
 

Item Name	Fluoxetine hcl
CAS NO.	56296-78-7
Apparence	White Powder
Molecular Formula	C17H19ClF3NO
Form	Powder&Capsules
Package	Aluminum Bag;Drums
Purity	99%min
Advantage	OEM;ODM
Certificate	ISO9001/SGS/HALAL
Storage	Store in cool & dry place; Keep away from strong light and high heat.
Shelf life	24 months when properly stored
Usage	Pharmaceutical intermediates
Payment Term	T/T,Western Union,Money Gram or Trade Assurance;
Delivery	DHL,EMS,FedEx,TNT,UPS,etc.

2.What is Fluoxetine ?

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant. Fluoxetine inhibits the uptake of serotonin by a nerve cells (neurons) and helps people with depression, panic, anxiety, or obsessive-compulsive symptoms.

Fluoxetine is a prescription medicine used to treat major depressive disorder, bulimia nervosa (an eating disorder), obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder (PMDD).
 

3.How does Fluoxetine work?

Fluoxetine binds to the presynaptic serotonin receptor resulting in negative allosteric modulation of the receptor complex, thereby blocking recycling of serotonin by the presynaptic receptor. Inhibition of serotonin reuptake by fluoxetine enhances serotonergic function through serotonin accumulation in the synaptic space, resulting in long-term desensitization and downregulation of 5HT1 (serotonin) receptors leading to antidepressant, antiobsessional and antibulimic effects via various nerve pathways in the brain.

4.What's the main function of Fluoxetine?

Fluoxetine was shown to be effective for depression in six-week-long double-blind controlled trials, where it also alleviated anxiety and improved sleep. Fluoxetine was better than placebo for the prevention of depression recurrence when the patients, who originally responded to fluoxetine, were treated for a further 38 weeks. Efficacy of fluoxetine for geriatric, as well as pediatric, depression was also demonstrated in placebo-controlled trials.

Research suggests that a significant part of the resistance to the SSRIs paroxetine (Paxil) and citalopram(Celexa) can be explained by the genetic variation of Pgp transporter. Paroxetine and citalopram, which are Pgp substrates, are actively transported from the brain by this protein. Fluoxetine is not a substrate of Pgp, and thus a switch from paroxetine or citalopram to fluoxetine may be beneficial to the nonresponders.

Fluoxetine is frequently used to treat major depression, obsessive compulsive disorder, bulimia nervosa,panic disorder, body dysmorphic disorder, premenstrual dysphoric disorder, and trichotillomania. Caution should be taken when using any SSRI for bipolar disorder as this can increase the likelihood of mania; however, fluoxetine can be used with an antipsychotic (such as quetiapine) for bipolar. It has also been used for cataplexy, obesity, and alcohol dependence,as well as binge eating disorder.

Medical uses:

Fluoxetine is frequently used to treat major depressive disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), bulimia nervosa, panic disorder, premenstrual dysphoric disorder, and trichotillomania.It has also been used for cataplexy, obesity, and alcohol dependence,as well as binge eating disorder.It has also been tried as a treatment for autism spectrum disorders with moderate success in adults.

Obsessive-compulsive disorder:

The efficacy of fluoxetine in the treatment of obsessive-compulsive disorder (OCD) was demonstrated in two randomized multicenter phase III clinical trials. The pooled results of these trials demonstrated that 47% of completers treated with the highest dose were "much improved" or "very much improved" after 13 weeks of treatment, compared to 11% in the placebo arm of the trial.The American Academy of Child and Adolescent Psychiatry state that SSRIs, including fluoxetine, should be used as first-line therapy in children, along with cognitive behavioral therapy (CBT), for the treatment of moderate to severe OCD.

Panic disorder:

The efficacy of fluoxetine in the treatment of panic disorder was demonstrated in two 12-week randomized multicenter phase III clinical trials that enrolled patients diagnosed with panic disorder, with or without agoraphobia. In the first trial, 42% of subjects in the fluoxetine-treated arm were free of panic attacks at the end of the study, vs. 28% in the placebo arm. In the second trial, 62% of fluoxetine treated patients were free of panic attacks at the end of the study, vs. 44% in the placebo arm.

Bulimia nervosa:

A 2011 systematic review of seven trials which compared fluoxetine to a placebo in the treatment of bulimia nervosa; six of which found a statistically significant reduction in symptoms such as vomiting and binge eating.However, no difference was observed between treatment arms when fluoxetine and psychotherapy were compared to psychotherapy alone.